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FK 506, a novel immunosuppressive agent, was first 
used to reverse rejection in liver recipients who had 
failed to respond to conventional therapy.' The successful 
outcome of the initial study has led to clinical trials of FK 
506 as the primary immunosuppressive agent for liver 
allografts and other organ transplants. 2-4 Ongoing studies 
include dosage protocols for optimal immunosuppression 
without significant side effects. Monitoring plasma levels 
of FK 506 in the transplant patient is performed using an 
enzyme-linked immunosorbent assay (ELISA) in the pres-
ence of anti-FK 506 monoclonal antibody. S FK 506 exhib-
its strong immunosuppressive effect on in vitro models of 
T-cell activation including mixed lymphocyte reaction and 
secondary proliferative responses (PLT) of alloreactive T 
cells. 6 .7 Recently we have developed another method to 
monitor plasma levels of FK 506, a bioassay based on the 
inhibition of the PL T response of an alloreactive T-cell 
c1one. 8 Our results indicate that the levels of active FK 506 
determined by the bioassay are consistently lower than 
those measured by ELISA. 
Histologic examination of needle core biopsies differen-
tiate acute cellular rejection from other causes of liver 
allograft dysfunction. The major histologic signs of hepatic 
allograft rejection are: a predominantly mononuclear 
portal infiltrate and evidence of bile duel damage.9 Im-
munophenotypic analysis of this inflammatory infiltrate 
reveals the presence of CD4+ and CD8+ T cells. macro-
phages. monocytes. neutrophils. eosinophils. and B 
cells. lu Graft infiltrating lymphocytes can be propagated in 
vitro in the presence of tissue culture media supplemented 
with recombinant Interleukin 2 (rIL2). II In vitro propaga-
tion of lymphocytes from transplant biopsies has increased 
our understanding of the immunological events in rejec-
tion. We have shown that in cyclosporine (CyAHreated 
patients increased lymphocyte growth occurs in biopsies 
with proven histologic rejection. 12 In the present study we 
investigated the frequency of lymphocyte growth from 
liver allograft biopsies in FK 506-treated patients. We also 
examined the relationship between lymphocyte growth 
from biopsies with different histologic diagnoses and the 
plasma levels of FK 506 as determined by ELISA and 
bioassay. 
MATERIALS AND METHODS 
Patient Population 
Routine percutaneous li"'er biopsies were performed on hepatic 
allograft recipients routinely 10 days posttransplant (protocol 
biopsy) and when indicated by signs of hepatic dysfunction. One 
hundred thirty-seven biopsies from 92 patients were studied. All 
patients were maintained on baseline immunosuppression with 
FK 506 with low doses of steroids. I Histologic diagnosis of acute 
cellular rejection was based on criteria previously reported.9 
Generation of Lymphocyte Cultures From Liver Biopsies 
Lymphocyte cultures propagated from liver biopsies were ob-
tained using previously published methodologies."· 12 In brief. a 
small portion of each biopsy was divided into fragments and 
cultured in the presence of tissue culture medium containing riU 
(20 UlmL. Sandoz Pharmaceuticals. Basel. Switzerland). The 
cultures were obser>'ed on an inverted phase microscope for 
cellular outgrowth at 10-14 days. 
Drug Source 
FK 506 was supplied in crystalline form by Fugisawa Pharmaceu-
tical Corp (Osaka. Japan). A stock solution of 100 JLg/mL was 
prepared in methanol and kept at -4°C. 
Determination of FK 506 Levels in Plasma 
Five milliliters of heparinized blood were collected from each liver 
transplant recipient at the time of the biops y during the first 2 
months following transplantation. All blood samples were incu-
bated at 37°C for I hour prior to separation by centrifugation. The 
plasma was analyzed for FK 506 trough levels using an indirect 
ELISA ~ and a bioassay .8In the bioassay the plasma concentration 
of FK 506 was calculated from a standard inhibition curve. The 
calculations were made using a monolinear sigmoidal model curve 
fitting program (Statistical Analysis System. release 5.IS. SAS 
Institutes. Cary. Nc!. The ICSO was determined from a standard 
curve and is the concentration of FK 506 En~ mL) that caused 50% 
inhibition of the PL T response of an alloreactive T -cell line . The 
1050 was determined from the plasma inhibition curve. and is the 
dilution factor at which patient plasma induced 5O'.k inhibition of 
the PL T response of the same alloreactive T-cell line used to 
determine the ICSO. From these values. the plasma concentration 
of FK 506 was calculated as IC50 x 1050. 
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Fig 1. Correlation between biopsy growth and FK 506 plasma levels as determined by (A) bioassay and (8) ELISA. 
RESULTS 
Propagation of Lymphocy1e Cuhures From liver 
Allograft Biopsies 
Thirty-three percent (22 of (6) of biopsies with rejection 
yielded lymphocyte cultures. significantly higher (P = 
.001: chi-square test) than the 7% (5 of7\) growth obtained 
from biopsies without rejection. The latter biopsies had 
diagnoses of ischemic injury. cholestasis. viral infection. 
or nonspecific changes. These results suggest that propa-
gation of lymphocyte cultures from liver allografts is 
associated with histologic evidence of rejection. 
Relationship Between Lymphocyte Growth and Plasma 
Levels of FK 506 
FK 506 levels were determined in 33 plasma samples from 
24 patients at the time of liver allograft biopsy. Ten of 33 
biopsies yielded lymphocyte cultures. Nine of the 10 
cultures were from biopsies with histologic evidence of 
rejection (Fig I). One lymphocyte culture was propagated 
from a biopsy with ischemic injury. In contrast. only 6 of 
23 biopsies that failed to grow had histologic changes 
compatible with an early process of cellular rejection. and 
the rest of the "non-growers" (17 of 23) were protocol 
biopsies with no evidence of rejection. 
Bioassay FK 506 levels for 10 "growers" were signifi-
cantly lower than for 23 "non-growers" (P = .002; Mann-
Whitney U test) (Fig I). Using a cutoff point of 0.3 nglmL, 
we observed that 21 of 23 non-growers had FK 506 
concentration above this level. whereas 8 of 10 of the 
growers were equal or lower (P < .001 by chi-square test). 
In contrast. differences between growers and non-growers 
were considerably less for FK 506 levels measured by 
ELISA (P = .01; Mann-Whitney U test). However. no 
cutoff level could be established in ELISA-determined FK 
506 levels to ditrerentiate between grower and non-grower 
status. These data suggest that lymphocyte growth from 
histologically diagnosed rejection positive biopsies is asso-
ciated with low levels of bioactive FK 506. 
DISCUSSION 
This study was designed to assess the relationship between 
in vitro propagation of lymphocytes from liver allograft 
biopsies and plasma levels of FK 506. A highly significant 
correlation was found between low levels of biologically 
active FK 506 «0.3 nglmL) and the ability of liver 
allograft biopsies to propagate lymphocyte cultures. Most 
of the biopsies that grew lymphocytes exhibited histo-
pathologic changes compatible with acute cellular rejec-
tion. In contrast, ELISA measurements of FK 506 levels 
were less discriminatory between the "growers" and the 
"non-growers." The levels or FK 506 determined in 
ELISA were consistently higher than those measured by 
bioassay.8 Considering the likelihood that FK 506 will be 
metabolized after administration. it seems possible that 
ELISA detects both biologically active drug and non-
active metabolites in the blood. In contrast, only the 
bioactive drug is detected by the bioassay.8 
The liver is the primary site or FK 506 metabolism. 13 
Jain et aI have shown that hepatic dysfunction has a 
1408 
profound effect on the metabolism and pharmacokinetics 
of FK 506. 14 In patients where the perioperative graft 
dysfunction did not resolve promptly. the ELISA plasma 
levels of FK 506 rose significantly. IS However. the bioas-
say FK 506 levels in this group of patients were much 
lower than that expected according to the ELISA mea-
surement (unpublished data). This lack of correlation be-
tween the two methods indicates that during severe he-
patic dysfunction the metabolism of FK 506 is altered. 
resulting in accumulation of biologically non-active metab-
olites. In contrast. in patients with stable liver allograft 
function there was a good correlation between the two FK 
506 measurements although the bioassay measured levels 
were consistently lower than levels determined by 
ELlSA.8 Studies are currently in progress to analyze the 
factors affecting FK 506 metabolism and their effect on 
bioassay FK 506 plasma levels. 
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